Tsingke Biotech Showcases AI Biomanufacturing Platforms at Festival of Biologics 2025

October 29, 2025
Beijing Tsingke Biotech presented its AI-powered biomanufacturing platforms at the 2025 Festival of Biologics in Basel, featuring solutions for gene and RNA design, antibody discovery, and scalable biologics production.

Beijing-based Tsingke Biotech Co., Ltd. showcased its AI-powered biomanufacturing platforms at the 2025 Festival of Biologics in Basel, announced in a press release. The event gathered over 2,000 biotech experts from 50 countries to explore innovations in biologics research and production.

Tsingke presented integrated solutions covering gene and RNA design, antibody discovery, and GMP-grade biologics manufacturing. The company highlighted how AI and next-generation sequencing are redefining antibody and protein engineering, enabling early process validation during discovery.

Describing itself as a full-stack "Gene Factory," Tsingke demonstrated capabilities in high-throughput gene synthesis, chemically modified oligonucleotides for ADC, PROTAC, and AOC research, and optimized nucleic acid purification and LNP encapsulation. These tools aim to link laboratory-scale research with industrial-scale manufacturing.

Tsingke’s ISO 13485–certified facilities and automated production systems support its goal of accelerating drug discovery and genetic engineering through digital design and precision synthesis.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Life Sciences

10/29
ExaCare AI Raises $30M Series A to Expand AI Platform for Skilled Nursing Facilities
10/29
Harbour BioMed Launches Fully Human Generative AI HCAb Model
10/29
MCG Health and Allegheny Health Network to Present on AI in Utilization Management at ACMA 2025
10/29
CareSet Names Sepideh Naseri Chief Data and Analytics Officer
10/29
ID.me and Flexpa Partner to Strengthen Health Data Access and Security

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more

You May Also Like